For example, in a phase 1 clinical trial in T1D patients using an epitope of proinsulin (C19-A3), treatment resulted in increased serum IL-10 levels and improved glycemic control in the group which received 10 μg of peptide (Thrower et al., 2009). This evidence concerns the gene IL10 and type 1 diabetes mellitus.